Urteste SA (URT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Urteste SA (URT) has a cash flow conversion efficiency ratio of -0.185x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-4.41 Million ≈ $-1.21 Million USD) by net assets (zł23.79 Million ≈ $6.55 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Urteste SA market cap and net worth for the company's overall valuation and market capitalisation.
Urteste SA - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Urteste SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Urteste SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Urteste SA ranked by their cash flow conversion efficiency. See debt repayment capacity of Urteste SA to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Blue Shark Power System SA
PA:MLBSP
|
N/A |
|
Canuc Resources Corp
V:CDA
|
-0.981x |
|
Fidelity Special Values
LSE:FSV
|
0.010x |
|
Lleidanetworks Serveis Telematics SA
MC:LLN
|
0.270x |
|
Redflow Ltd
AU:RFX
|
-0.849x |
|
111 Inc
NASDAQ:YI
|
-3.363x |
|
Precio Fishbone AB (publ)
ST:PRCO-B
|
0.044x |
|
Carboclor
BA:CARC
|
0.037x |
Annual Cash Flow Conversion Efficiency for Urteste SA (2019–2025)
The table below shows the annual cash flow conversion efficiency of Urteste SA from 2019 to 2025. View Urteste SA (URT) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | zł34.58 Million ≈ $9.52 Million |
zł10.64 Million ≈ $2.93 Million |
0.308x | +235.68% |
| 2024-12-31 | zł24.11 Million ≈ $6.64 Million |
zł-5.47 Million ≈ $-1.50 Million |
-0.227x | -18.22% |
| 2023-12-31 | zł27.74 Million ≈ $7.64 Million |
zł-5.32 Million ≈ $-1.46 Million |
-0.192x | +71.57% |
| 2022-12-31 | zł5.62 Million ≈ $1.55 Million |
zł-3.79 Million ≈ $-1.04 Million |
-0.675x | -154.05% |
| 2021-12-31 | zł9.69 Million ≈ $2.67 Million |
zł-2.57 Million ≈ $-708.19K |
-0.266x | +73.22% |
| 2020-12-31 | zł1.37 Million ≈ $375.68K |
zł-1.35 Million ≈ $-372.56K |
-0.992x | -197.46% |
| 2019-12-31 | zł1.20 Million ≈ $328.95K |
zł-398.48K ≈ $-109.67K |
-0.333x | -- |
About Urteste SA
Urteste S.A. engages in the research and development of diagnostic tests for cancers in Poland. It offers diagnostic tests for pancreas, prostate, kidney, colon, liver, biliary tract, bile ducts, stomach, lung, esophagus, ovary, endometrium, blood, breast, and brain. The company was incorporated in 2021 and is based in Gdansk, Poland.